Inhibikase Therapeutics, Inc.
IKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.02 | 0.06 | -0.01 |
| FCF Yield | -8.49% | -267.23% | -139.57% | -53.41% |
| EV / EBITDA | -6.15 | 0.09 | -0.32 | 0.00 |
| Quality | ||||
| ROIC | -30.07% | -173.19% | -84.19% | -38.19% |
| Gross Margin | 0.00% | -5,127.77% | 94.55% | -266.35% |
| Cash Conversion Ratio | 0.70 | 0.95 | 0.96 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -56.20% | -43.88% | 40.30% |
| Free Cash Flow Growth | -5.79% | -2.87% | -23.06% | -1,165.95% |
| Safety | ||||
| Net Debt / EBITDA | 2.05 | 0.43 | 0.38 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | -243.49 | -741.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.01 | 106.16 |
| Cash Conversion Cycle | -13,101.47 | -17.33 | -1,703.93 | -18.61 |